Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Washington University School of Medicine |
---|---|
Information provided by: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00736944 |
This phase two trial will determine the tumor response rate at the primary site and at involved regional nodes to two cycles of an IC regimen of weekly Abraxane and cetuximab given in combination with cisplatin and 5-FU in patients with local regionally advanced HNSCC.
Condition | Intervention | Phase |
---|---|---|
Squamous Cell Carcinoma of the Head and Neck |
Drug: Abraxane Drug: Cetuximab Drug: Cisplatin Drug: 5-FU Radiation: Radiation (Post induction) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Active Control, Single Group Assignment, Efficacy Study |
Official Title: | Trial to Determine the CR Rate at the Primary Tumor Site After 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head & Neck Carcinoma Treated With Definitive Concurrent Cisplatin & Radiation Therapy |
Estimated Enrollment: | 30 |
Study Start Date: | October 2008 |
Estimated Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Induction chemotherapy followed by Radiation therapy plus Cisplatin Induction chemotherapy: Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3. Post-Induction: Radiation - Monday-Friday weeks 1-7 with concurrent Cisplatin 100 mg/m2 IVPB on radiation day 1, 22, and 42. |
Drug: Abraxane
100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
Drug: Cetuximab
400 mg/m2 IVPB, Day 1, cycle 1
Drug: Cetuximab
250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
Drug: Cisplatin
75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
Drug: 5-FU
750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
Radiation: Radiation (Post induction)
Monday-Friday, weeks 1-7
Drug: Cisplatin
(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
|
2: Experimental
Induction chemotherapy followed by Radiation therapy plus Cetuximab Induction chemotherapy: Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3. Post-Induction: Radiation - Monday-Friday weeks 1-7 with concurrent Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB |
Drug: Abraxane
100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
Drug: Cetuximab
400 mg/m2 IVPB, Day 1, cycle 1
Drug: Cetuximab
250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
Drug: Cisplatin
75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
Drug: 5-FU
750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
Radiation: Radiation (Post induction)
Monday-Friday, weeks 1-7
Drug: Cetuximab
(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
|
Primary objective:
To determine the clinical CR rate (CR-p) at the primary tumor site to an IC regimen of weekly Abraxane and cetuximab with CF (ACCF) given for two cycles (over 6 weeks) in patients with locally advanced non-metastatic HNSCC. The assessment of primary tumor site response will be performed by the treating physician by careful clinical examination using WHO criteria. Radiographic studies will also be performed to assess primary tumor site response but will be used primarily to confirm lack of disease progression that may not be detected based on clinical examination alone.
The secondary objectives include:
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion
Exclusion Criteria:
Contact: Douglas Adkins, M.D. | 314-747-7402 | dadkins@dom.wustl.edu |
United States, Missouri | |
Washington University | Recruiting |
St. Louis, Missouri, United States, 63110 | |
Contact: Douglas Adkins, M.D. 314-747-7402 dadkins@dom.wustl.edu | |
Sub-Investigator: Brian Nussenbaum, M.D. | |
Sub-Investigator: Wade Thorstad, M.D. | |
Sub-Investigator: David Kuperman, M.D. | |
Sub-Investigator: Barry Siegel, M.D. | |
Sub-Investigator: Farrokh Dehdashti, M.D. | |
Sub-Investigator: James Lewis, M.D. | |
Sub-Investigator: Bruce Haughey, MBBS | |
Sub-Investigator: Kim Trinkaus, Ph.D. |
Principal Investigator: | Douglas Adkins, M.D. | Washington Univerisity |
Responsible Party: | Washington University ( Douglas Adkins, M.D. ) |
Study ID Numbers: | 08-0911 |
Study First Received: | August 13, 2008 |
Last Updated: | October 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00736944 |
Health Authority: | United States: Food and Drug Administration |
Squamous cell carcinoma Cetuximab Carcinoma Epidermoid carcinoma Cisplatin Paclitaxel Head and Neck Neoplasms |
Fluorouracil Carcinoma, squamous cell Neoplasms, Squamous Cell Carcinoma, Squamous Cell Carcinoma, squamous cell of head and neck Neoplasms, Glandular and Epithelial |
Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Radiation-Sensitizing Agents Antineoplastic Agents Therapeutic Uses |
Mitosis Modulators Tubulin Modulators Physiological Effects of Drugs Antimitotic Agents Antineoplastic Agents, Phytogenic Pharmacologic Actions |